000			01320 a2200337 4500
005			20250516084327.0
264		0	_c20120618
008			201206s 0 0 eng d
022			_a1873-5835
024	7		_a10.1016/j.leukres.2012.02.027 _2doi
040			_aNLM _beng _cNLM
100	1		_aTibes, Raoul
245	0	0	_aEvolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques. _h[electronic resource]
260			_bLeukemia research _cJun 2012
300			_a664-71 p. _bdigital
500			_aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aBiomarkers, Tumor _xanalysis
650	0	4	_aClinical Trials as Topic _xtrends
650	0	4	_aEndpoint Determination _xtrends
650	0	4	_aHumans
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdiagnosis
650	0	4	_aMedical Oncology _xmethods
650	0	4	_aModels, Biological
650	0	4	_aMonitoring, Physiologic _xmethods
650	0	4	_aPrognosis
650	0	4	_aSensitivity and Specificity
650	0	4	_aTreatment Outcome
700	1		_aMesa, Ruben A
773	0		_tLeukemia research _gvol. 36 _gno. 6 _gp. 664-71
856	4	0	_uhttps://doi.org/10.1016/j.leukres.2012.02.027 _zAvailable from publisher's website
999			_c21662240 _d21662240